The melanocortin 1 receptor (MC1R or alpha melanocytestimulating hormone receptor) is a key protein regulating skin and hair pigmentation. Melanin synthesis is largely modulated by the agonistic ...

Orally administered PL8177 is designed to target melanocortin-1 receptors on the surface of cells lining the colon. In a Phase 1 clinical trial, the oral version of PL8177 was shown to effectively ...

Perspective, Therapeutics announced that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of 212PbVMT01, ...

The team then designed an astatine-211(211 At)-labeled α-melanocyte-stimulating hormone (α-MSH) peptide analog called [211 At]NpG-GGN4c to specifically target melanocortin-1 receptors (MC1R ...

Six-month open-label study showed clinically meaningful improvements in kidney function and disease in patients with Type 2 diabetic nephropathy. 71% achieved a >30% reduction in UP/Cr, a key ...

a selective melanocortin-1 receptor (MC1R) agonist, in patients with active ulcerative colitis (UC). This study was designed to assess the safety, tolerability, and effectiveness of PL8177 when ...

Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo after eight weeks of treatment. Clinical Response (statistically significant): Demonstrated in 78% of PL8177 ...

Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo after eight weeks of treatment. Clinical Response (statistically significant): Demonstrated in 78% of PL8177-treated ...